UPCC 05519: Single-Arm Study Of Carboplatin Weekly Taxane And Ramucirumab In Advanced NSCLC After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

Site Image

Study Overview

The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.

Participants for this study, will be recruited from the physician practices of the University of Pennsylvania.

  • Study Identifier: 833759

Recruitment Status

Enrolling By Invitation

For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com